Evolving models of the immunopathogenesis of T cell–mediated drug allergy: The role of host, pathogens, and drug response
KD White, WH Chung, SI Hung, S Mallal… - Journal of Allergy and …, 2015 - Elsevier
Immune-mediated (IM) adverse drug reactions (ADRs) are an underrecognized source of
preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is …
preventable morbidity, mortality, and cost. Increasingly, genetic variation in the HLA loci is …
Antiretroviral therapy and management of HIV infection
PA Volberding, SG Deeks - The Lancet, 2010 - thelancet.com
Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic
disease. There are now 17 drugs in common use for HIV treatment. Patients who can access …
disease. There are now 17 drugs in common use for HIV treatment. Patients who can access …
Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a …
S Croxford, A Kitching, S Desai, M Kall… - The Lancet Public …, 2017 - thelancet.com
Background Deaths in HIV-positive people have decreased since the introduction of highly
active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing …
active antiretroviral therapy (HAART) in 1996. Fewer AIDS-related deaths and an ageing …
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label …
B Clotet, J Feinberg, J van Lunzen, MA Khuong-Josses… - The Lancet, 2014 - thelancet.com
Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING …
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
with potent antiviral activity and a favourable safety profile. We compared dolutegravir with …
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a …
PE Sax, E DeJesus, A Mills, A Zolopa, C Cohen… - The Lancet, 2012 - thelancet.com
Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the
CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate …
CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate …
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
Objectives To estimate life expectancy for people with HIV undergoing treatment compared
with life expectancy in the general population and to assess the impact on life expectancy of …
with life expectancy in the general population and to assess the impact on life expectancy of …
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989 …
MP de Béthune - Antiviral research, 2010 - Elsevier
It is almost 20 years since NNRTIs were identified as a new class of antiretroviral drugs for
the treatment of HIV-1 infection. Although they belong to different and diverse chemical …
the treatment of HIV-1 infection. Although they belong to different and diverse chemical …
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled …
JM Molina, P Cahn, B Grinsztejn, A Lazzarin, A Mills… - The Lancet, 2011 - thelancet.com
Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred
antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non …
antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non …
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn… - The Lancet infectious …, 2011 - thelancet.com
Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …